DMD CRISPR/Cas9 gene therapy (University of California Los Angeles)

N/A

Report date: 2025/01/26 19:12:46

Base Information

Drug NameDMD CRISPR/Cas9 gene therapy (University of California Los Angeles)
Drug Alias NameDuchenne muscular dystrophy gene therapy (University of California Los Angeles)
ClassificationBiologics
Mechanisms of ActionDystrophin gene transference
TargetsDystrophin
Therapy Area/IndicationsMuscular Dystrophy, Duchenne
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of California, Los Angeles
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of CaliforniaUniversity Of California, Los Angeles
Inactive CompaniesN/A
Active IndicationsMuscular Dystrophy, Duchenne
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A